Influx Healthtech Limited (INFLUX)
Latest quarterly results (H2 FY26)
INFLUX delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 67.16% of the INFLUX shares traded on NSE were taken to delivery, against the stock's own 20-session average of 74.37%. That is close to its usual level.
Delivery in the last 5 sessions: 80.0% · 68.2% · 75.0% · 69.2% · 67.2%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
The National Stock Exchange of India Limited (NSE) has rejected Influx Healthtech Limited's waiver application and imposed a monetary fine of Rs 1,55,000 plus GST, aggregating to Rs 1,82,900. The penalty pertains to a 31-day non-compliance regarding the delayed submission of half-yearly consolidated financial results for the period ended March 31, 2026. The company originally filed results on May 20, 2026, but later submitted revised half-yearly consolidated figures on July 2, 2026, following the formation of a new subsidiary on February 3, 2026. Management noted the financial impact is restricted solely to the penalty amount and will present the matter to the Board.
- NSE imposed a fine of Rs 1,55,000 plus GST, aggregating to Rs 1,82,900
- Penalty imposed for 31 days of non-compliance under Regulation 33 of SEBI LODR Regulations
- Results for the period ended March 31, 2026 were originally submitted on May 20, 2026 and revised on July 2, 2026
- Delay related to consolidated reporting after incorporating wholly owned subsidiary Olahey Wellness Private Limited on February 3, 2026
Influx Healthtech Limited concluded its 6th Annual General Meeting on September 18, 2026, with 100% of polled votes cast in favor of all agenda items. Shareholders approved the audited financial statements for FY26 and the re-appointment of Mrs. Shirin Munir Ahmed Chandniwala as Whole-time Director. Total voter turnout was 76.25% across 17.65 million polled shares out of 23.15 million total shares. Both ordinary resolutions passed without any opposing votes.
- Both ordinary resolutions passed with 100% votes in favor (17,652,768 votes)
- Total voter turnout stood at 76.25% of the total 23,150,400 outstanding shares
- Promoter participation was 100% (17,023,464 shares) while institutional turnout was 35.54%
- Total number of registered shareholders on the record date (September 11, 2026) was 1,313
Influx Healthtech Limited conducted its 6th Annual General Meeting on September 18, 2026, via video conferencing. The meeting transacted ordinary business, including the adoption of audited financial statements for FY26 and the reappointment of Whole-time Director Shirin Munir Ahmed Chandniwala, who retired by rotation. No questions or queries were raised by shareholders during the Q&A session. Final voting results will be submitted separately to the exchange.
- 6th Annual General Meeting held on September 18, 2026, starting at 12:00 PM IST and concluding at 12:09 P.M.
- Adopted Annual Audited Financial Statements (Standalone and Consolidated) for the financial year ended March 31, 2026
- Considered re-appointment of Mrs. Shirin Munir Ahmed Chandniwala (DIN: 08459623) as Whole-time Director
- Statutory Auditor's Report and Secretarial Audit (MR-3) contained zero qualifications or adverse remarks
Influx Healthtech Limited announced it has dispatched letters to shareholders without registered email addresses under Regulation 36(1)(b) of SEBI LODR Regulations. The letter provides web-links to access the FY 2025-26 Annual Report and notice of the upcoming 6th Annual General Meeting (AGM). The AGM is scheduled to take place on September 18, 2026, at 12:00 PM IST via Video Conferencing. The cut-off date used for determining eligible recipients was August 21, 2026.
- 6th Annual General Meeting scheduled for September 18, 2026, at 12:00 PM IST via VC/OAVM
- Letters dispatched to shareholders without registered emails based on the cut-off date of August 21, 2026
- SEBI Master Circular compliance reminder issued to physical security holders regarding KYC and dematerialization
Influx Healthtech Limited has released the notice for its 6th Annual General Meeting (AGM) scheduled for Friday, September 18, 2026, via Video Conferencing/OAVM. Alongside the notice, the company submitted its Annual Report for the financial year 2025-2026. The cut-off date to determine shareholder voting eligibility is September 11, 2026, with remote e-voting open from September 15 to September 17, 2026. Key agenda items include the adoption of FY26 audited financial statements and the reappointment of retiring Whole-time Director Mrs. Shirin Munir Ahmed Chandniwala.
- 6th AGM to be conducted via Video Conferencing on September 18, 2026, at 12:00 PM IST
- Cut-off date for determining e-voting eligibility fixed as September 11, 2026
- Remote e-voting window open from September 15, 2026 (09:00 AM) to September 17, 2026 (05:00 PM)
- Cut-off date for dispatch of AGM notice and Annual Report was August 21, 2026
Influx Healthtech Limited announced the outcome of its Board of Directors meeting held on August 26, 2026. The Board approved the Director's Report and its annexures for the financial year ended March 31, 2026. The company's 6th Annual General Meeting (AGM) has been scheduled for September 18, 2026. Additionally, M/s. PNK & Co., Practicing Company Secretaries, was appointed as the Scrutinizer for the AGM proceedings.
- 6th Annual General Meeting fixed for September 18, 2026
- Approved Directors Report and annexures for the financial year ended March 31, 2026
- Appointed M/s. PNK & Co. (CP No. 23912) as Scrutinizer for the upcoming AGM
- Board meeting conducted on August 26, 2026, from 2:30 PM to 3:30 PM
Financial Performance
Revenue Growth by Segment
Total revenue grew 39% YoY to INR 66.8 Cr in H1 FY26. Nutraceuticals (90% of revenue) grew 36.3% from INR 44.1 Cr to INR 60.1 Cr; Cosmetics (5% of revenue) grew 61.9% from INR 2.1 Cr to INR 3.4 Cr; Ayurvedic (4% of revenue) grew 107.7% from INR 1.3 Cr to INR 2.7 Cr; Others grew 20% from INR 0.5 Cr to INR 0.6 Cr.
Geographic Revenue Split
The company exports to 11 countries. While specific regional percentages are not disclosed, management highlighted a significant focus on the US market following NSF certification and US FDA registration, with expectations for production to 'boom' in the coming months.
Profitability Margins
PAT margin improved significantly to 15.0% in H1 FY26, up 329 bps from 11.7% in H1 FY25. Net Profit Ratio for FY25 was 12.76% compared to 11.15% in FY24. Management expects these margins to be sustainable over the next three years due to the current product profile and client set.
EBITDA Margin
EBITDA margin stood at 22.0% in H1 FY26, a 302 bps increase from 18.9% in H1 FY25. Absolute EBITDA rose 61% YoY to INR 14.7 Cr, driven by operational efficiency and increased sales in key segments.
Capital Expenditure
Planned capex of INR 5-6 Cr for H2 FY26, including a retort plant and veterinary high-speed machines. The company is investing INR 11 Cr specifically for the veterinary segment (kibbles), targeting an asset turnover of 5-7x on this investment.
Credit Rating & Borrowing
Debt-Equity ratio improved by 57.30% to 0.006 in FY25 from 0.014 in FY24. Debt Service Coverage Ratio improved by 6890.32% to 22,523.99x as the company repaid interest-bearing loans.
Operational Drivers
Raw Materials
Not specifically named in the documents, but identified as a key risk factor where price fluctuations impact margin volatility.
Capacity Expansion
Current capacity utilization is 65% for Nutraceuticals, 60% for Cosmetics, and 75% for Pet/Homecare. The company plans a 2.5x capacity expansion based on FY25 figures using IPO proceeds, including a new beverage line with a capacity of 10,000 bottles per hour.
Raw Material Costs
Cost of materials consumed was INR 37.5 Cr in H1 FY26, representing 56.1% of revenue, compared to 61.7% in H1 FY25 (INR 29.7 Cr). This 26% increase in absolute cost was lower than the 39% revenue growth, indicating better procurement or pricing.
Manufacturing Efficiency
The company operates 3 manufacturing units. Fixed asset turnover is targeted at 5-6 times. Automation initiatives, such as the automated beverage plant expected by June, are aimed at improving throughput.
Strategic Growth
Expected Growth Rate
100%
Growth Strategy
The company aims to double revenue by FY27 through a 2.5x capacity expansion funded by IPO proceeds. Key strategies include entering the Ready-to-Drink (RTD) market via retort manufacturing, launching a high-capacity beverage line (10,000 bottles/hr), and expanding the veterinary segment (kibbles) which is expected to grow faster than nutraceuticals.
Products & Services
Multi-nutritional tablets, dietary supplements, cosmetics, ayurvedic/herbal products, veterinary feeds, and home care products.
Brand Portfolio
The company operates primarily as a CDMO (Contract Development and Manufacturing Organization) for clients like Carbamide (which accounts for 70-80% of its own business with Influx).
New Products/Services
New beverage line (RTD), retort packaging systems, and high-speed veterinary kibble production. Veterinary revenue is expected to grow from its current 1% base to a significant contributor over 3-4 years.
Market Expansion
Targeting the US export market following NSF certification. Tanzania market entry is pending a virtual audit scheduled for December 11.
Strategic Alliances
Strong alignment with client Carbamide; considering a dedicated manufacturing line/unit for them to support their hyper-growth and fixed volume take-off.
External Factors
Industry Trends
The wellness industry is shifting toward certified, clean-label products. The Indian manufacturing sector for pet food is currently dominated by imports (Pedigree, Royal Canin), providing a significant import-substitution opportunity for local CDMOs like Influx.
Competitive Landscape
Operates in a fragmented CDMO market with pricing pressure. Competes with both domestic manufacturers and international imports in the veterinary and nutraceutical spaces.
Competitive Moat
Moats include a 98% client retention rate, industry-leading certifications (NSF, US FDA, GMP, HACCP, ISO 22000), and a formulation-driven innovation model that creates high switching costs for clients.
Macro Economic Sensitivity
Sensitive to global demand for wellness products and preventive healthcare trends. Revenue is subject to fluctuations in raw material prices and forex swings.
Consumer Behavior
Rising interest in preventive healthcare and 'clean-label' wellness products is driving demand for the company's nutraceutical and ayurvedic segments.
Geopolitical Risks
Potential delays in international audits (e.g., Tanzania) due to political situations, though the company currently reports being on track for its December audit.
Regulatory & Governance
Industry Regulations
Operations are governed by FSSAI (India), AYUSH (Ayurveda), and US FDA regulations. Compliance includes GMP, HACCP, and ISO 22000:2018 Food Safety Management Systems.
Environmental Compliance
The company notes execution risks related to ESG compliance as a factor requiring agile innovation.
Risk Analysis
Key Uncertainties
High revenue concentration in the nutraceutical segment (90%) and a limited client base (Top 10 = 30-40%) pose risks if market demand shifts or key clients migrate.
Geographic Concentration Risk
While exporting to 11 countries, the company faces execution risks in expanding its international footprint and meeting evolving global regulatory standards.
Third Party Dependencies
36% of procurement is concentrated among the top 10 suppliers, creating potential supply chain vulnerability.
Technology Obsolescence Risk
The company is mitigating technology risks by investing in automation, such as the new 10,000 bottle/hr beverage line and retort systems.
Credit & Counterparty Risk
Debtor days improved to 100 days in H1 FY26 from 113 days in FY25, indicating improving receivables quality.
